Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Pfizer
Femme et Homme Max 99 ans
Pfizer Inc
MAJ Il y a 4 ans
A RANDOMIZED PHASE 2 TRIAL OF PF 00299804 VERSUS ERLOTINIB FOR THE TREATMENT OF ADVANCED NON SMALL CELL LUNG CANCER AFTER FAILURE OF AT LEAST ONE PRIOR CHEMOTHERAPY REGIMEN
To assess Progression Free Survival (PFS) in patients randomized to PF 00299804 and to erlotinib
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Pfizer Inc. 235 East 42nd Street, New York, 10017
MAJ Il y a 4 ans
SUNITINIB TREATMENT OF RENAL ADJUVANT CANCER (S-TRAC): A RANDOMIZED DOUBLE-BLIND PHASE 3 STUDY OF ADJUVANT SUNITINIB VS. PLACEBO IN SUBJECTS WITH HIGH RISK RCC
To demonstrate an improvement in disease-free survival (DFS) in high risk (per modified UISS criteria) subjects with RCC randomly assigned to adjuvant sunitinib 50 mg schedule 4/2: 4 weeks on, 2 weeks...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Wyeth Research Division of Wyeth Pharmaeuticals Inc. (A Pfizer Company)
MAJ Il y a 4 ans
A Phase I/II Safety and Exploratory Pharmacodynamic Study of Intravenous Temsirolimus (CCI-779) in Pediatric Subjects with Relapsed/Refractory Solid Tumors
Part 1 (Part 1 is now closed): Primary Objective - To evaluate the safety of IV temsirolimus given once weekly to children with solid tumors with disease that is recurrent or refractory to standard th...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Pfizer Pharma GmbH
MAJ Il y a 4 ans
Six week, double-blind, placebo controlled Phase III trial evaluating the efficacy, safety and pharmacokinetics of flexible doses of oral ziprasidone in adolescent subjects with schizophrenia
1. To establish efficacy of oral ziprasidone compared to placebo in the treatment of adolescent subjects with schizophrenia, as measured by the change from baseline to Week 6 in Brief Psychiatric Rati...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Pfizer Inc. 235 East 42nd Street, New York, NY10017, USA
MAJ Il y a 4 ans
PROSPECTIVE STUDY OF OPHTHALMOLOGIC FUNCTION IN PATIENTS RECEIVING LINEZOLID FOR TWO MONTHS OR GREATER
Primary Objective: To prospectively identify and characterize optic nerve toxicity in subjects receiving long-term (2 months or greater) linezolid therapy.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Pfizer Inc.235 East 42nd Street, New York, NY 10017
MAJ Il y a 4 ans
A Phase 2/3 Randomized, Controlled, Double-Masked, Multi-Center, Comparative Trial, in Parallel Groups, to Compare the Safety and Efficacy of Intravitreous Injections of 0.3 mg Pegaptanib Sodium (Macugen), Given as Often as Every 6 Weeks for 2 years, to Sham Injections, in Subjects with Diabetic Macular Edema (DME) Involving the Center of the Macula
The objective of this trial will be to confirm the safety and compare the efficacy of pegaptanib sodium when subjects are given intravitreous injections of 0.3 mg/eye versus sham injections in a 1:1 r...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Pfizer, S. A
MAJ Il y a 4 ans
An 8-week, multicentre, randomised, double-blind, placebo-controlled, flexible dose study of Pregabalin (300-600 mg/day) and Venlafaxine XR (75-225 mg/day) for the acute treatment of DSM-IV Generalized Anxiety Disorder in outpatients
To evaluate the efficacy of Pregabalin and Venlafaxine XR (extended release) compared to placebo in the treatment of GAD).
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Pfizer Ltd. Ramsgate Road, Sandwich, Kent CT13 9NJ, UK
MAJ Il y a 4 ans
A 6-MONTH, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER, PARALLEL GROUP, MAINTENANCE OF EFFECT STUDY OF ESREBOXETINE (PNU-165442G) ADMINISTERED ONCE DAILY (QD) IN PATIENTS WITH FIBROMYALGIA
To evaluate the efficacy of ESRBX (QD) compared with placebo treatment in assessing the maintenance of effect for the treatment of pain intensity and function associated with fibromyalgia.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Pfizer Inc.235 East 42nd Street, New York, NY 10017
MAJ Il y a 4 ans
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF THE SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB IN SUBJECTS WITH OSTEOARTHRITIS OF THE HIP OR KNEE ESTUDO MULTICÊNTRICO DE FASE 3, ALEATORIZADO, EM DUPLA OCULTAÇÃO, CONTROLADO POR PLACEBO SOBRE A EFICÁCIA ANALGÉSICA E A SEGURANÇA DA ADMINISTRAÇÃO SUBCUTÂNEA DE TANEZUMAB EM DOENTES COM OSTEOARTRITE DA ANCA OU DO JOELHO
•Demonstrate superior efficacy of tanezumab 5 mg and 2.5 mg administered subcutaneously (SC) every 8 weeks versus placebo at Week 24.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Pfizer Inc. 235 East 42nd Street, New York, 10017
MAJ Il y a 4 ans
Study to test the safety and efficacy of Glasdegib (PF-04449913) versus placebo in patients with Myelofibrosis
Lead-in Cohort • To assess the safety and tolerability of PF-04449913 in patients with primary or secondary MF who have been previously treated with ≥1 JAKi. Randomized Cohort • To compare...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Précédent
12
13
14
15
16
17
18
19
20
21
Suivant